Hepatic Arterial Infusion Floxuridine with Systemic Therapy for Liver-dominant Metastatic Pancreatic Adenocarcinoma: Results of the PANCPUMP Phase II Pilot Study

Background Hepatic progression is common in metastatic pancreatic ductal adenocarcinoma (PDAC). We evaluated hepatic arterial infusion (HAI) floxuridine (FUDR) added to systemic chemotherapy in selected patients with synchronous liver-dominant metastatic PDAC. Methods PANCPUMP was a prospective, single-center, single-arm phase II pilot study of 14 patients with synchronous PDAC liver metastases and stable disease or response after at least 2 months of systemic chemotherapy. Patients underwent HAI pump placement and received up to six 28 day cycles of HAI FUDR with systemic therapy. The primary endpoint was 1 year hepatic progression-free survival, with a prespecified target of 40%. Results Seven patients (50%) remained free of hepatic progression at 1 year, meeting the primary endpoint. Median time to hepatic progression was 15.7 months when deaths without hepatic progression were censored; median all-site progression-free interval and overall survival were 14.5 and 14.0 months, respectively. Five patients (35.7%) survived at least 24 months. Biochemical hepatotoxicity was frequent; two delayed grade 3 gastroduodenal artery (GDA)/catheter-associated vascular complications occurred. Among 10 patients with paired European Organisation for Research and Treatment of Cancer Core Quality-of-Life questionnaire assessments, the mean global health/quality-of-life score was 69.2 at baseline and 70.0 at first follow-up ( p = 0.91). Conclusions HAI FUDR plus systemic therapy met the prespecified hepatic-control endpoint in a highly selected cohort. These proof-of-concept findings support further study of regional hepatic therapy alongside contemporary systemic treatment.

Authors

Publication Details

Journal
Annals of Surgical Oncology
Published
2026-11-21
DOI
https://doi.org/10.1245/s10434-026-20940-6
Primary Topic
Pancreatic and Hepatic Oncology Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Hepatic Arterial Infusion Floxuridine with Systemic Therapy for Liver-dominant Metastatic Pancreatic Adenocarcinoma: Results of the PANCPUMP Phase II Pilot Study

Jason M. Aubrey, Randa Preihs, Alexandra Bengel, Mathew H. Chung et al.
Annals of Surgical Oncology
Pancreatic and Hepatic Oncology Research
article

Hepatic Arterial Infusion Floxuridine with Systemic Therapy for Liver-dominant Metastatic Pancreatic Adenocarcinoma: Results of the PANCPUMP Phase II Pilot Study

Jason M. Aubrey, Randa Preihs, Alexandra Bengel, Mathew H. Chung, G. Paul Wright, Sreenivasa Rao Chandana, M. Mura Assifi, Chantelle Koch, Shannon M. Smith, Lisa Martin
article en

Abstract

Background Hepatic progression is common in metastatic pancreatic ductal adenocarcinoma (PDAC). We evaluated hepatic arterial infusion (HAI) floxuridine (FUDR) added to systemic chemotherapy in selected patients with synchronous liver-dominant metastatic PDAC. Methods PANCPUMP was a prospective, single-center, single-arm phase II pilot study of 14 patients with synchronous PDAC liver metastases and stable disease or response after at least 2 months of systemic chemotherapy. Patients underwent HAI pump placement and received up to six 28 day cycles of HAI FUDR with systemic therapy. The primary endpoint was 1 year hepatic progression-free survival, with a prespecified target of 40%. Results Seven patients (50%) remained free of hepatic progression at 1 year, meeting the primary endpoint. Median time to hepatic progression was 15.7 months when deaths without hepatic progression were censored; median all-site progression-free interval and overall survival were 14.5 and 14.0 months, respectively. Five patients (35.7%) survived at least 24 months. Biochemical hepatotoxicity was frequent; two delayed grade 3 gastroduodenal artery (GDA)/catheter-associated vascular complications occurred. Among 10 patients with paired European Organisation for Research and Treatment of Cancer Core Quality-of-Life questionnaire assessments, the mean global health/quality-of-life score was 69.2 at baseline and 70.0 at first follow-up ( p = 0.91). Conclusions HAI FUDR plus systemic therapy met the prespecified hepatic-control endpoint in a highly selected cohort. These proof-of-concept findings support further study of regional hepatic therapy alongside contemporary systemic treatment.

Annals of Surgical Oncology
Pancreatic and Hepatic Oncology Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon
Hepatic Arterial Infusion Floxuridine with Systemic Therapy for Liver-dominant Metastatic Pancreatic Adenocarcinoma: Results of the PANCPUMP Phase II Pilot Study — Jason M. Aubrey, Randa Preihs, et al. · Annals of Surgical Oncology (2026) | TGRS Research Map | TGRS